Grail, Inc.
A healthcare company that makes the Galleri test, a single blood draw that can screen for dozens of types of cancer at once by spotting DNA fragments shed by tumors. The company was born in 2016 when DNA-sequencing firm Illumina spun it out after researchers noticed, while testing pregnant women, that tumor DNA could be found in a routine blood sample. Its name comes from the "holy grail" of medicine—a simple, non-invasive test that catches cancer early.
Sold 169.4K
Granted 31.1K · Sold 82.3K
Sold 58.5K
Sold 1.5K
Granted 6.1K
Granted 5.9K
Granted 5.5K
Granted 5.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Ragusa Robert PChief Executive Officer, Director · 6 transactions | -27.3% | 518.6K | — | — | 169.4K |
| Ofman Joshua J.Chief Executive Officer, Director · 8 transactions | -11.3% | 402.3K | 31.1K | — | 82.3K |
| Freidin AaronChief Financial Officer · 6 transactions | -18.3% | 260.7K | — | — | 58.5K |
| Partridge Andrew JohnChief Growth Officer · 1 transaction | — | 163.7K | — | — | 1.5K |
| Summe Gregory LDirector · 2 transactions | +15.6% | 45.2K | 6.1K | — | — |
| Chase William JDirector · 2 transactions | +16% | 42.7K | 5.9K | — | — |
| Krevans SarahDirector · 1 transaction | +14.8% | 42.6K | 5.5K | — | — |
| Mizell StevenDirector · 2 transactions | +16.1% | 42.6K | 5.9K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 6 months: -311.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.